Methods and compositions for live attenuated viruses
Embodiments herein relate to compositions of and methods for live viruses. In certain embodiments, a live, attenuated virus composition includes, but is not limited to, one or more live, attenuated viruses and compositions to reduce inactivation and/or degradation of the live, attenuated virus. In other embodiments, the live, attenuated virus composition may be a vaccine composition. In yet other compositions, a live, attenuated virus composition may include at least one carbohydrate, at least one protein and at least one high molecular weight surfactants for reducing inactivation and/or degradation of the live, attenuated virus.
1. A virus composition comprising:
one or more live, attenuated flaviviruses; and a stabilizing composition comprising serum albumin and trehalose,
wherein the one or more live, attenuated flaviviruses consists of one or more Dengue viruses;
wherein the serum albumin is serum albumin from a vertebrate species, and is present at a concentration of 0.001 to 3.0% (w/v);
wherein the trehalose is present at a concentration of at least 15% (w/v); and
wherein the composition is capable of reducing the inactivation of the one or more live, attenuated Dengue viruses.
2. A method for decreasing inactivation of one or more live, attenuated Dengue viruses comprising: combining one or more live, attenuated Dengue viruses with a stabilizing composition comprising serum albumin and trehalose,
wherein the serum albumin is serum albumin from a vertebrate species, and is present at a concentration of 0.001 to 3.0% (w/v);
wherein the trehalose is present at a concentration of at least 15% (w/v); and
wherein the composition is capable of reducing the inactivation of the one or more live, attenuated Dengue viruses.
3. The method of claim 2 , further comprising partially or wholly dehydrating the combination.
4. The method of claim 3 , further comprising partially or wholly re-hydrating the combination prior to administration.
5. The method of claim 2 , wherein the composition increases the shelf life of an aqueous Dengue virus composition.
6. The method of claim 2 , wherein the composition decreases inactivation of an aqueous live, attenuated Dengue virus for 24 hours or greater.
7. The method of claim 2 , wherein the composition decreases inactivation of an aqueous live, attenuated Dengue virus during one or more freeze and thaw cycles.
8. The method of claim 2 , wherein the composition comprises one or more live, attenuated Dengue viruses and is administered to a subject to reduce the onset of a health condition caused by the Dengue viruses.
9. A kit for decreasing inactivation of Dengue viruses comprising:
at least one container; and
a composition comprising one or more live, attenuated Dengue viruses; and a stabilizing composition comprising: serum albumin and trehalose,
wherein the serum albumin is serum albumin from a vertebrate species, and is present at a concentration of 0.001 to 3.0% (w/v);
wherein the trehalose is present at a concentration of at least 15% (w/v); and
wherein the composition is capable of reducing the inactivation of the one or more live, attenuated Dengue viruses.
10. The kit of claim 9 , wherein the serum albumin is human serum albumin.
11. The virus composition of claim 1 , wherein the serum albumin is recombinant serum albumin.
12. The virus composition of claim 1 , wherein the serum albumin from a vertebrate species is from a human, a canine, or a bovine source.
13. The virus composition of claim 1 , wherein the virus composition further comprises one or more poly(ethylene oxide) and poly(propylene oxide) (EO-PO) block copolymers, and the one or more EO-PO block copolymers include poloxamer 407.
14. The virus composition of claim 12 , wherein the serum albumin from a vertebrate species is from a human source.